Quantcast
Last updated on June 1, 2012 at 19:03 EDT

    News - Cara Therapeutics

    Unigene's Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics' Successful Completion of its Phase 1 Study Using Unigene's Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845
    2012-04-03 02:27:43

    BOONTON, N.J., April 3, 2012 /PRNewswire/ -- Unigene Laboratories, Inc.

    Unigene's Proprietary Peptelligence(TM) Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
    2011-11-30 07:02:00

    BOONTON, N.J., Nov.

    Cara Therapeutics Completes Phase I Study of Pain Drug
    2008-08-06 09:01:05

    Cara Therapeutics has completed Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain.

    More News (3 articles) »
    Breaking News
    Space
    Science
    Technology
    Health
    CES 2012
    More...
    Streaming Video
    Top Picks
    Science
    Health
    More...
    Images and Photos
    Images of the Day
    Image Galleries
    Wallpapers
    More...
    Space Exploration
    Astronomy
    Human Spaceflight
    Ask the Astronomer
    More...
    Science and Research
    Instruments
    Calculator
    Ask the Scientist
    More...
    Technology
    Ask the Expert
    Technology Reviews
    More...
    My Health
    Health
    More...
    © 2002-2012 redOrbit.com. All rights reserved
    All other copyrights remain the property of their respective owners